제약 전사적 자원 계획(ERP) : 시장 점유율 분석, 산업 동향 및 통계 데이터, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pharmaceutical eRP market size is projected to expand from USD 4.43 billion in 2025 and USD 4.82 billion in 2026 to USD 8.08 billion by 2031, registering a CAGR of 10.92% between 2026 and 2031.

This report is Segmented by Deployment Mode (Cloud-Based ERP, On-Premise ERP, and Hybrid ERP), Module (Manufacturing Management, Quality and Compliance Management, Supply Chain Management, and More), Organization Size (Large Enterprises, Small and Medium Enterprises), End User (Pharmaceutical Manufacturers, Cmos, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Pharmaceutical Enterprise Resource Planning Market Trends and Insights

Demand for Cloud-Based Validated ERP Platforms

Pharmaceutical manufacturers are moving workloads to the cloud to reduce capital expenditure, unlock real-time batch visibility, and cut validation timelines. SAP, Oracle, and Microsoft introduced pre-validated life sciences suites that embed GxP documentation, enabling companies to comply with 21 CFR Part 11 without maintaining on-premises environments. Contract manufacturing organizations prefer multi-tenant cloud architectures that isolate sponsor data yet share common quality modules, enabling faster onboarding and harmonized electronic batch records. However, data-residency rules in China and Russia force hybrid deployments that blend public-cloud financials with on-premise manufacturing execution systems.

Tightening Global Serialization Deadlines

The United States Drug Supply Chain Security Act completed its phased rollout in 2025, requiring manufacturers, wholesalers, and dispensers to integrate unit-level track-and-trace into their ERP systems. The European Union Falsified Medicines Directive granted Italy and Greece extensions until 2027, creating a two-speed environment that favors modular, country-specific templates. Serialization drives demand for blockchain-enabled ERP integrations that provide immutable audit trails and real-time verification against national repositories REUTERS.COM.

High CSV Costs for SMEs

Computer system validation can consume up to 30% of an ERP project budget for small and medium enterprises, extending go-live dates by up to a year. External consultants bill USD 150-250 per hour, straining limited IT budgets. Vendors offer shared validation documentation, yet regulators insist that manufacturers retain ultimate responsibility for compliance. The burden is heavier for contract manufacturers that must satisfy divergent sponsor requirements.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Expansion of Contract Manufacturing Organizations
2. AI-Enabled Predictive Quality and Batch-Release Analytics
3. Shortage of Pharma-Savvy ERP Implementation Talent

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Cloud-based solutions accounted for 62% of revenue in 2025, and this share of the Pharmaceutical ERP market is set to grow at a 11.80% CAGR through 2031. Hybrid models satisfy jurisdictions that restrict patient data movement while unlocking cloud scalability for non-GxP functions. The Pharmaceutical ERP market size for cloud deployments is projected to command the majority of new spend by 2031. Early adopters report significantly lower validation costs after switching from on-premises suites. Contract manufacturing organizations dominate uptake because multi-tenant clouds enable sponsor segregation and rapid onboarding.

On-premises deployments persist in China and Russia, where data localization laws remain strict. Facilities with legacy equipment lack OPC-UA connectivity, so migrating to the public cloud can trigger costly re-validation of entire production lines. Hybrid architectures let manufacturers migrate financials and human resources to cloud services while retaining manufacturing execution on-site. Vendors that automate audit-trail reconciliation shorten CSV cycles from 18 months to six months, accelerating Pharmaceutical ERP market adoption among compliance-focused firms.

Quality and compliance accounted for 28.40% of 2025 revenue, reflecting the regulatory focus. This slice of the Pharmaceutical ERP market share underpins every major deployment, especially where DSCSA and EU FMD demand serialization. Manufacturing management modules orchestrate scheduling, procurement, and maintenance, offering process visibility across multi-site networks.

Research and development modules are expected to grow at a 12.60% CAGR as innovators integrate AI into formulation design and clinical-trial workflows. The Pharmaceutical ERP market for Research and Development tools, while still smaller than the quality management market, is growing fastest because AI shortens experimentation cycles. Supply chain modules benefit from blockchain pilots that create immutable product provenance, and human resources tools map employee training records to GxP tasks, ensuring only qualified staff perform critical operations.

Geography Analysis

North America led with 34.90% of 2025 revenue, driven by stringent DSCSA rules and an innovation-oriented manufacturing base. The Pharmaceutical ERP market size in the United States benefits from early cloud validation pilots and broad AI experimentation. Canada leverages proximity to the United States to position itself as a biologics contract manufacturing hub, making cross-border batch visibility a must-have.

Europe maintains second position. The EU Falsified Medicines Directive mandates serialization, and the Corporate Sustainability Reporting Directive compels Scope 3 carbon accounting. These rules favor integrated ERP suites over point solutions. Data-residency considerations under GDPR encourage hybrid architectures that host patient data locally and move financial data to global clouds.

Asia-Pacific is the fastest-growing region, expected to advance at 10.20% through 2031. India's USD 2 billion incentive propels local firms into export markets that demand FDA and EMA compliance. China's USD 1.5 billion infrastructure push and centralized procurement reforms motivate domestic CMOs to embrace international GxP standards. Japan pilots AI batch-release analytics to offset labor shortages.

South America is growing more slowly due to macroeconomic volatility, though Brazil and Argentina are investing selectively in ERP modernization. The Middle East and Africa remain nascent but promising, as Saudi Arabia and the United Arab Emirates develop local pharma manufacturing to reduce reliance on imports.

1. SAP SE
2. Oracle Corporation
3. Microsoft Corporation
4. Infor, Inc.
5. QAD Inc.
6. BatchMaster Software Pvt. Ltd.
7. Aptean, Inc.
8. Sage Group plc
9. Epicor Software Corporation
10. SYSPRO (Pty) Ltd.
11. IFS AB
12. Acumatica, Inc.
13. Oracle NetSuite LLC
14. Slingshot Enterprise Business Systems, Inc.
15. RxERP LLC
16. Dexciss Technology Private Limited
17. Blue Link Associates Limited
18. Deacom, LLC
19. Plex Systems, Inc.
20. Workday, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition * Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Demand for Cloud-Based Validated ERP Platforms
  • 4.2.2 Tightening Global Serialization Deadlines (DSCSA, EU FMD)
  • 4.2.3 Rapid Expansion of Contract Manufacturing Organizations
  • 4.2.4 AI-Enabled Predictive Quality and Batch-Release Analytics
  • 4.2.5 Government Incentives for Digital Pharma Plants
  • 4.2.6 Growing Need for End-to-End ESG and Carbon Accounting
• 4.3 Market Restraints
  • 4.3.1 High CSV (Computer System Validation) Costs for SMEs
  • 4.3.2 Shortage of Pharma-Savvy ERP Implementation Talent
  • 4.3.3 Cyber-Security and Data-Residency Concerns in Public Cloud
  • 4.3.4 Legacy MES/LIMS Integration Complexities
• 4.4 Industry Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Intensity of Competitive Rivalry
  • 4.7.2 Threat of New Entrants
  • 4.7.3 Threat of Substitutes
  • 4.7.4 Bargaining Power of Suppliers
  • 4.7.5 Bargaining Power of Buyers
• 4.8 Impact of Macroeconomic Factors on the Market

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 5.1 By Deployment Mode
  • 5.1.1 Cloud-Based ERP
  • 5.1.2 On-Premise ERP
  • 5.1.3 Hybrid ERP
• 5.2 By Module
  • 5.2.1 Manufacturing Management
  • 5.2.2 Quality and Compliance Management
  • 5.2.3 Supply Chain Management
  • 5.2.4 Financial Management
  • 5.2.5 Sales and Marketing
  • 5.2.6 Human Resources Management
  • 5.2.7 Other Modules
• 5.3 By Organization Size
  • 5.3.1 Large Enterprises
  • 5.3.2 Small and Medium Enterprises
• 5.4 By End User
  • 5.4.1 Pharmaceutical Manufacturers
  • 5.4.2 Contract Manufacturing Organizations
  • 5.4.3 Pharmaceutical Distributors
  • 5.4.4 Biotechnology Companies
  • 5.4.5 Contract Research Organizations
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Rest of North America
  • 5.5.2 South America
    • 5.5.2.1 Brazil
    • 5.5.2.2 Argentina
    • 5.5.2.3 Rest of South America
  • 5.5.3 Europe
    • 5.5.3.1 Germany
    • 5.5.3.2 United Kingdom
    • 5.5.3.3 France
    • 5.5.3.4 Italy
    • 5.5.3.5 Spain
    • 5.5.3.6 Rest of Europe
  • 5.5.4 Asia-Pacific
    • 5.5.4.1 China
    • 5.5.4.2 India
    • 5.5.4.3 Japan
    • 5.5.4.4 South Korea
    • 5.5.4.5 Australia and New Zealand
    • 5.5.4.6 Rest of Asia-Pacific
  • 5.5.5 Middle East
    • 5.5.5.1 Saudi Arabia
    • 5.5.5.2 United Arab Emirates
    • 5.5.5.3 Turkey
    • 5.5.5.4 Rest of Middle East
  • 5.5.6 Africa
    • 5.5.6.1 South Africa
    • 5.5.6.2 Nigeria
    • 5.5.6.3 Egypt
    • 5.5.6.4 Rest of Africa

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.4.1 SAP SE
  • 6.4.2 Oracle Corporation
  • 6.4.3 Microsoft Corporation
  • 6.4.4 Infor, Inc.
  • 6.4.5 QAD Inc.
  • 6.4.6 BatchMaster Software Pvt. Ltd.
  • 6.4.7 Aptean, Inc.
  • 6.4.8 Sage Group plc
  • 6.4.9 Epicor Software Corporation
  • 6.4.10 SYSPRO (Pty) Ltd.
  • 6.4.11 IFS AB
  • 6.4.12 Acumatica, Inc.
  • 6.4.13 Oracle NetSuite LLC
  • 6.4.14 Slingshot Enterprise Business Systems, Inc.
  • 6.4.15 RxERP LLC
  • 6.4.16 Dexciss Technology Private Limited
  • 6.4.17 Blue Link Associates Limited
  • 6.4.18 Deacom, LLC
  • 6.4.19 Plex Systems, Inc.
  • 6.4.20 Workday, Inc.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment